Novartis has been shopping: According to Kauppalehti, Novartis is acquiring the British company Myricx Bio for 1.1 billion. The deal also includes up to 400 million euros in milestone payments. Myricx is a privately held cancer drug developer. Does this step on Faron’s toes at all in terms of drug development, or unlikely?
10 Likes